- Home
- GNLX vs DHF Comparison
GNLX vs DHF Comparison
Compare GNLX & DHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GNLX | DHF |
|---|---|---|
| Founded | 2001 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 202.4M | 185.7M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | GNLX | DHF |
|---|---|---|
| Price | $2.44 | $2.53 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $19.75 | N/A |
| AVG Volume (30 Days) | 265.8K | ★ 451.1K |
| Earning Date | 03-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.65% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.99 | $2.06 |
| 52 Week High | $8.54 | $2.39 |
Technical Indicators
Market Signals| Indicator | GNLX | DHF |
|---|---|---|
| Relative Strength Index (RSI) | 30.99 | 51.62 |
| Support Level | $2.31 | $2.47 |
| Resistance Level | $2.55 | $2.53 |
| Average True Range (ATR) | 0.18 | 0.02 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 15.26 | 50.00 |
Price Performance
Historical ComparisonAbout GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. The fund invests predominantly in fixed-income securities of below-investment-grade credit quality.